Review
Open access
Oct 2026
Emerging landscape of antibody-drug conjugates in lung cancer: a clinical review.
Lung cancer is a heterogeneous disease, and while targeted therapies and immunotherapies have improved patient outcomes, 5-year overall survival remains poor at approximately 20%. Antibody-drug conjugates (ADCs) target tumors using a targeted antibody that delivers a cytotoxic payload with clinically proven antitumor a...
Henry Pickett, J. Arias-Romero, Jeremy Fricke et al.
· Trends in Cancer · 0 citations